文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺放疗后复发模式与镓68-PSMA PETCT时机:对潜在挽救治疗的启示

Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: Implications for potential salvage.
PubMed 文献 · Radiother Oncol · 2022-02-18

研究纳入114例接受根治性外照射放疗联合雄激素剥夺治疗的非转移性前列腺癌患者,在随访PSA升高时行镓68-PSMA PETCT。91.2%患者发现提示复发的摄取,复发检出概率随扫描时PSA升高而增加(AUC=0.82),潜在可挽救复发概率随PSA升高而下降(AUC=0.68)。

要点

  • 114例非转移性前列腺癌放疗后PSA升高行镓68-PSMA PETCT,91.2%见提示复发摄取。
  • 扫描时PSA≤2、≤5、≤10、>10 ng/mL时阳性率分别为75%、87%、89%、100%。
  • 潜在可挽救复发59/104例(56.7%),PSA≤2 ng/mL时为67%,PSA>10 ng/mL时仅38%。

核心结论

  • 根治性前列腺放疗后PSA升高时早期行镓68-PSMA PETCT可检出多数复发病灶并识别适合局灶挽救治疗的寡复发。

研究设计与样本

  • 研究纳入接受根治性外照射放疗联合雄激素剥夺治疗的非转移性前列腺癌患者,分析随访中PSA升高后行镓68-PSMA PETCT者的复发模式。
  • 共114例患者纳入分析,69%为高危;放疗为大分割者占57%(中度40%、极度17%),前列腺中位EQD2为78.5 Gy。
  • 放疗至镓68-PSMA PETCT中位时间4.3年(IQR 2.4-6.4),扫描时中位PSA 4.7 ng/mL(IQR 2.6-10.7)。

主要发现

  • 91.2%患者见提示复发的摄取,扫描时PSA≤2、≤5、≤10、>10 ng/mL时阳性率分别为75%、87%、89%、100%。
  • 镓68-PSMA PETCT检出复发的概率随扫描时PSA升高而增加(AUC=0.82)。
  • 摄取为局部者20例(17.5%)、寡转移者39例(34.2%)、多转移者45例(39.5%)。
  • 复发潜在可挽救者59/104例(56.7%),扫描时PSA≤2 ng/mL时为67%,PSA>10 ng/mL时仅38%。
  • 复发潜在可挽救的概率随扫描时PSA升高而下降(AUC=0.68)。

关键数值与推荐

  • 前列腺外复发病灶≤5个定义为寡转移。
  • 局部复发和寡转移复发被认为适合局灶挽救治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To study patterns of recurrence in Ga68-PSMA PETCT at rising serum PSA after radical radiotherapy for non-metastatic prostate cancer. METHODS: Among patients with non-metastatic prostate cancer treated with radical external beam radiotherapy and androgen deprivation therapy, those who underwent Ga68-PSMA PETCT for rising PSA during follow up were analysed. Patterns of recurrence in Ga68-PSMA PETCT were studied. Extra-prostatic recurrences ≤5 were considered oligometastases. Local and oligometastatic recurrences were deemed suitable for focal salvage therapy. Probabilities of identifying recurrent lesion and potentially salvageable recurrences in Ga68-PSMA PETCT in relation to PSA were calculated. RESULTS: Total 114 patients were included (69% high-risk). Radiotherapy was hypofractionated in 57% (moderate 40%, extreme 17%), with median prostate EQD2 78.5 Gy. Median time from radiotherapy to Ga68-PSMA PETCT was 4.3 years (IQR 2.4-6.4), with median PSA 4.7 ng/mL (IQR 2.6-10.7) at scan. Uptake suggesting recurrence was observed in 91.2% patients, with positivity of 75%, 87%, 89%, and 100% at PSA thresholds ≤2, ≤5, ≤10, and >10 ng/mL respectively. Probability of detecting recurrence in Ga68-PSMA PETCT increased with higher PSA at scan (AUC = 0.82). Uptake was local in 20 (17.5%), oligometastatic in 39 (34.2%), and polymetastatic in 45 (39.5%) patients. Recurrence was potentially salvageable in 59/104 (56.7%) patients, being 67% at PSA ≤2 ng/mL but only 38% at PSA >10 ng/mL. Probability of recurrence being potentially salvageable declined with increasing PSA at scan (AUC = 0.68). CONCLUSION: Early Ga68-PSMA PETCT for rising PSA after definitive prostate radiotherapy detected majority of recurrent lesions and identified oligorecurrences amenable to focal salvage therapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Maitre P, Sood S, Pathare P, et al. Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: Implications for potential salvage. Radiother Oncol. 2022. PMID: 35189154. doi:10.1016/j.radonc.2022.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。